ALPHANATE provides a pharmacokinetic profile comparable to natural FVIII
ALPHANATE pharmacokinetic profile in hemophilia A treatment
- ALPHANATE pharmacokinetics are comparable to endogenous factor VIII (FVIII)1
- With ALPHANATE, the mean in vivo half-life of FVIII is 18 hours1
- In the absence of von Willebrand factor (VWF) in plasma, the half-life of FVIII is 1 hour1
ALPHANATE pharmacokinetic profile in VWD treatment
ALPHANATE pharmacokinetics are comparable to other FVIII/VWF concentrates regardless of FVIII:VWF ratio.
Pharmacokinetics in von Willebrand disease (VWD)1
|Number of patients||14*|
|Half-life VWF:RCo||7.67 + 3.32 hours (mean ± SD)|
|Half-life FVIII:C||21.58 + 7.79 hours (mean ± SD)|
|Half-life VWF:Ag||13.06 + 2.20 hours (mean ± SD)|
|In vivo recovery for VWF:RCo||3.29 + 1.46 IU VWF:RCo/dL (mean ± SD)|
* 11 of 14 (79%) of the study patients had type 3 VWD.
FVIII, factor VIII; SD, standard deviation; VWD, von Willebrand disease; VWF, von Willebrand factor.